Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009763 | 0.91 | MMP3 (0.82) | MMP3MEN1KMT2AUSP7ENPP2 | |
| SCHEMBL4001097 | 0.91 | MMP3 (0.82) | MMP3MEN1KMT2AUSP7ENPP2 | |
| SCHEMBL30504282 | 0.89 | MMP3 (0.79) | MMP3MEN1KMT2AUSP7ENPP2 | |
| SCHEMBL28581912 | 0.85 | MMP3 (0.74) | MMP3MEN1ESR1KMT2AUSP7 | |
| SCHEMBL338712 | 0.85 | MMP3 (0.73) | MMP3MEN1KMT2AENPP2PIK3CA | |
| SCHEMBL4006124 | 0.85 | MMP3 (0.72) | MMP3MEN1KMT2AUSP7ENPP2 | |
| SCHEMBL8338095 | 0.82 | MMP3 (0.70) | MMP3USP7ENPP2ABL1PIK3CD | |
| SCHEMBL17873550 | 0.82 | MMP3 (0.70) | MMP3ENPP2KDM4ETDP1 | |
| SCHEMBL18069859 | 0.82 | MMP3 (0.70) | MMP3ENPP2CYP3A4KDM4ETDP1 | |
| SCHEMBL11050113 | 0.82 | MMP3 (0.70) | MMP3MEN1ESR1KMT2AHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1193250-B1 | PHENYL SULFAMATE DERIVATIVES | TEIKOKU HORMONE MFG CO LTD (JP) | 2008-06-04 | — | — | EP | disclosed |
| CN-1178906-C | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ���Ͽع�����˾ | 2004-12-08 | — | — | CN | disclosed |
| US-6762205-B1 | STEROID SULFATASE INHIBITORS WITHOUT ESTROGENIC SIDE EFFECT ACTION | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1193250-A1 | PHENYL SULFAMATE DERIVATIVES | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| CN-1261876-A | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ABBOTT LAB (US) | 2000-08-02 | — | — | CN | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | MMP3 3/4885MEN1 2722/4885ESR1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.